BACKGROUND: Filaggrin gene (FLG) mutations contribute to the development of eczema and asthma, but their contribution to sensitization and hay fever remains unclear. METHODS: FLG mutations R501X, 2282del4 and R2447X were genotyped in the Prevention and Incidence of Asthma and Mite Allergy birth cohort (n = 934) to evaluate longitudinally, for up to 8 years, their association with eczema, sensitization, asthma, hay fever and their interaction with cat exposure. RESULTS: The combined FLG mutations were significantly associated with eczema at all ages when occurring in the first year of life (OR = 2.0; 95% CI: 1.4-2.8). Combined FLG mutations were associated with both atopic and nonatopic eczema, as well as asthma (OR = 3.7; 95% CI: 1.8-7.5). When the FLG 2282del4 mutation was analysed separately, it was significantly associated with the development of eczema during the first year, having eczema up to 8 years and sensitization at the age of 8 years, which was enhanced by early-life cat exposure (ORs being 8.2; 95% CI: 2.6-25.9, 6.0; 95% CI: 3.2-11.3 and 5.4; 95% CI: 1.2-23.6 respectively). FLG 2282del4 was significantly associated with hay fever from the age 5 years onwards (OR = 3.9; 95% CI: 1.5-10.5). CONCLUSIONS: FLG mutations are associated both with atopic and nonatopic eczema starting in the first year of life. FLG mutations combined with eczema in the first year of life are associated with a later development of asthma and hay fever, a clear example of the atopic march. We confirm that cat exposure enhances the effect of a FLG mutation on the development of eczema and sensitization.
BACKGROUND:Filaggrin gene (FLG) mutations contribute to the development of eczema and asthma, but their contribution to sensitization and hay fever remains unclear. METHODS:FLG mutations R501X, 2282del4 and R2447X were genotyped in the Prevention and Incidence of Asthma and Mite Allergy birth cohort (n = 934) to evaluate longitudinally, for up to 8 years, their association with eczema, sensitization, asthma, hay fever and their interaction with cat exposure. RESULTS: The combined FLG mutations were significantly associated with eczema at all ages when occurring in the first year of life (OR = 2.0; 95% CI: 1.4-2.8). Combined FLG mutations were associated with both atopic and nonatopic eczema, as well as asthma (OR = 3.7; 95% CI: 1.8-7.5). When the FLG2282del4 mutation was analysed separately, it was significantly associated with the development of eczema during the first year, having eczema up to 8 years and sensitization at the age of 8 years, which was enhanced by early-life cat exposure (ORs being 8.2; 95% CI: 2.6-25.9, 6.0; 95% CI: 3.2-11.3 and 5.4; 95% CI: 1.2-23.6 respectively). FLG2282del4 was significantly associated with hay fever from the age 5 years onwards (OR = 3.9; 95% CI: 1.5-10.5). CONCLUSIONS:FLG mutations are associated both with atopic and nonatopic eczema starting in the first year of life. FLG mutations combined with eczema in the first year of life are associated with a later development of asthma and hay fever, a clear example of the atopic march. We confirm that cat exposure enhances the effect of a FLG mutation on the development of eczema and sensitization.
Authors: Adrian Chan; William Terry; Hongmei Zhang; Wilfried Karmaus; Susan Ewart; John W Holloway; Graham Roberts; Ramesh Kurukulaaratchy; Syed Hasan Arshad Journal: Clin Exp Allergy Date: 2018-02 Impact factor: 5.018
Authors: Ali H Ziyab; Wilfried Karmaus; Hongmei Zhang; John W Holloway; Susan E Steck; Susan Ewart; Syed Hasan Arshad Journal: Int Arch Allergy Immunol Date: 2014-09-23 Impact factor: 2.749
Authors: Manuel A R Ferreira; Melanie C Matheson; David L Duffy; Guy B Marks; Jennie Hui; Peter Le Souëf; Patrick Danoy; Svetlana Baltic; Dale R Nyholt; Mark Jenkins; Catherine Hayden; Gonneke Willemsen; Wei Ang; Mikko Kuokkanen; John Beilby; Faang Cheah; Eco J C de Geus; Adaikalavan Ramasamy; Sailaja Vedantam; Veikko Salomaa; Pamela A Madden; Andrew C Heath; John L Hopper; Peter M Visscher; Bill Musk; Stephen R Leeder; Marjo-Riitta Jarvelin; Craig Pennell; Dorret I Boomsma; Joel N Hirschhorn; Haydn Walters; Nicholas G Martin; Alan James; Graham Jones; Michael J Abramson; Colin F Robertson; Shyamali C Dharmage; Matthew A Brown; Grant W Montgomery; Philip J Thompson Journal: Lancet Date: 2011-09-10 Impact factor: 79.321
Authors: Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury Journal: J Am Acad Dermatol Date: 2013-11-27 Impact factor: 11.527
Authors: H Blakeway; V Van-de-Velde; V B Allen; G Kravvas; L Palla; M J Page; C Flohr; R B Weller; A D Irvine; T McPherson; A Roberts; H C Williams; N Reynolds; S J Brown; L Paternoster; S M Langan Journal: Br J Dermatol Date: 2020-02-11 Impact factor: 9.302